• Increase font size
  • Default font size
  • Decrease font size

Subscriber Only Content

More News

Breaking News

More News

RSS Subscription

Stem cells show extraordinary potential to treat various cancers

Could latest results mean that IMUC is close to securing a partnership? ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) announced today that its dendritic cell-based vaccination with cancer stem cells (CSCs) demonstrated a statistically significant survival benefit in a preclinical animal model of glioblastoma.

 
Oculus' CEO believes market will embrace the new FDA approved Microcyn® HydroGel

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS),  today announced that it has received new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new dermatology indications for Microcyn® Skin and Wound HydroGel.

 
Poniard is waiting for the FDA on SPEAR, and then on a partner

Is there a partner out there for picoplatin? This is obviously the most significant question for the company right now, in addition to what the FDA will say about the SCLC data

 
Why has BIEL been rising?
Shares of BioElectronics enjoyed a nice jump in price this week based on the release of an interview with CEO Andy Whelan
 
RxNews Recap for Tuesday 03-09-10. InterMune flys on FDA panel review. Facet BioTech bought out by Abbott.

Below is a list of the companies that made news in the healthcare sector on Tuesday, March 9, 2010.

 
FDA lung experts back InterMune drug for rare lung disease
Federal health advisers on Tuesday voted in favor of an experimental drug from InterMune Inc., despite mixed evidence of whether it provides significant benefits for patients with a rare lung disease.  
 
More Articles...
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 155

Free Email Newsletter

Subscribe to our free email newsletter.

Sign Up For Phone Alerts

Video: Health News Reports